Search Results - "Raventós, Carles X"

Xpert Bladder Cancer Monitor for the Early Detection of Non-Muscle Invasive Bladder Cancer Recurrences: Could Cystoscopy Be Substituted? by Lozano, Fernando, Raventós, Carles X, Carrion, Albert, Dinarés, Carme, Hernández, Javier, Trilla, Enrique, Morote, Juan

“…XBM was prospectively assessed in spontaneous urine collected just before flexible cystoscopy and washing cytology carried out within the first 2 years…”
Get full text

Risk factors for positive findings in patients with high‐grade T1 bladder cancer treated with transurethral resection of bladder tumour (TUR) and bacille Calmette‐Guérin therapy and the decision for a repeat TUR by Orsola, Anna, Cecchini, Lluís, Raventós, Carles X., Trilla, Enric, Planas, Jacques, Landolfi, Stefania, De Torres, Inés, Morote, Juan

“…Study Type – Therapy (case series) Level of Evidence 4 OBJECTIVE To determine factors predictive of positive findings at the 3‐month follow‐up evaluation…”
Get full text

Improved prediction of biochemical recurrence after radical prostatectomy by genetic polymorphisms by Morote, Juan, Del Amo, Jokin, Borque, Angel, Ars, Elisabet, Hernández, Carlos, Herranz, Felipe, Arruza, Antonio, Llarena, Roberto, Planas, Jacques, Viso, María J, Palou, Joan, Raventós, Carles X, Tejedor, Diego, Artieda, Marta, Simón, Laureano, Martínez, Antonio, Rioja, Luis A

“…Single nucleotide polymorphisms are inherited genetic variations that can predispose or protect individuals against clinical events. We hypothesized that…”
Get more information

Evaluation of the serum testosterone to prostate‐specific antigen ratio as a predictor of prostate cancer risk by Morote, Juan, Planas, Jacques, Ramirez, Cristobal, Gómez, Esther, Raventós, Carles X., Placer, José, Catalán, Roberto, De Torres, Inés M.

“…Study Type – Diagnostic (exploratory cohort)
 Level of Evidence 2b OBJECTIVE To analyse the ratio of serum testosterone (sT) to prostate‐specific antigen (PSA)…”
Get full text

The relationship between total and free serum testosterone and the risk of prostate cancer and tumour aggressiveness by Morote, Juan, Ramirez, Cristobal, Gómez, Esther, Planas, Jacques, Raventós, Carles X., De Torres, Inés M., Catalán, Roberto

“…OBJECTIVE To analyse the relationship between the levels of total and free serum testosterone and the risk of prostate cancer and tumour aggressiveness…”
Get full text

The relationship between daily calcium intake and bone mineral density in men with prostate cancer by Planas, Jacques, Morote, Juan, Orsola, Anna, Salvador, Carlos, Trilla, Enrique, Cecchini, Lluis, Raventós, Carles X.

“…OBJECTIVE To analyse the relationship between daily calcium intake (DCI) and bone mineral density (BMD) in patients with prostate cancer, and to assess if DCI…”
Get full text

Behavior of the PCA3 gene in the urine of men with high grade prostatic intraepithelial neoplasia by Morote, Juan, Rigau, Marina, Garcia, Marta, Mir, Carmen, Ballesteros, Carlos, Planas, Jacques, Raventós, Carles X., Placer, José, de Torres, Inés M., Reventós, Jaume, Doll, Andreas

“…Objective An ideal marker for the early detection of prostate cancer (PCa) should also differentiate between men with isolated high grade prostatic…”
Get full text

Failure to maintain a suppressed level of serum testosterone during long-acting depot luteinizing hormone-releasing hormone agonist therapy in patients with advanced prostate cancer by Morote, Juan, Esquena, Salvador, Abascal, José M, Trilla, Enrique, Cecchini, Luis, Raventós, Carles X, Catalán, Roberto, Reventós, Jaume

“…It was the aim of this study to analyze the failure rates in achieving or maintaining castrate levels of serum testosterone in patients with advanced prostate…”
Get more information

Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy by Morote, Juan, Orsola, Anna, Planas, Jacques, Trilla, Enrique, Raventós, Carles X, Cecchini, Lluís, Catalán, Roberto

“…We determined the testosterone castration level with clinical relevance in patients with prostate cancer on continuous androgen deprivation therapy. Secondary…”
Get more information

Individual variations of serum testosterone in patients with prostate cancer receiving androgen deprivation therapy by Morote, Juan, Planas, Jacques, Salvador, Carlos, Raventós, Carles X., Catalán, Roberto, Reventós, Jaume

“…OBJECTIVE To analyse individual variations in serum testosterone level, the cumulative rate of ‘breakthrough’ increases over castrate levels, and to evaluate…”
Get full text

Genetic predisposition to early recurrence in clinically localized prostate cancer by Borque, Ángel, del Amo, Jokin, Esteban, Luis M., Ars, Elisabet, Hernández, Carlos, Planas, Jacques, Arruza, Antonio, Llarena, Roberto, Palou, Joan, Herranz, Felipe, Raventós, Carles X., Tejedor, Diego, Artieda, Marta, Simon, Laureano, Martínez, Antonio, Carceller, Elena, Suárez, Miguel, Allué, Marta, Sanz, Gerardo, Morote, Juan

“…What's known on the subject? and What does the study add? Currently available nomograms to predict preoperative risk of early biochemical recurrence (EBCR)…”
Get full text

33% radius evaluation to assess bone mineral density in prostate cancer patients by Morote, Juan, Planas, Jacques, Mir, Maria Carmen, Raventós, Carles X., Encabo, Gloria, Doll, Andreas

“…Purpose Dual-energy X-ray absorptiometry (DXA) is the standard method to assess bone mineral density (BMD). The International Society for Clinical Densitometry…”
Get full text

Preoperative prediction of pathologically insignificant prostate cancer in radical prostatectomy specimens: the role of prostate volume and the number of positive cores by Raventós, Carles X, Orsola, Anna, de Torres, Inés, Cecchini, Lluís, Trilla, Enrique, Planas, Jacques, Morote, Joan

“…To determine clinical and biopsy features with predictive capacity to identify pathologically insignificant prostate cancer (pIPCa). pIPCa was defined as…”
Get more information

Is Tumor Budding a New Predictor for Early Cystectomy in pT1 High-Grade Bladder Cancer? by Raventós Busquets, Carles X, Semidey, M Eugenia, Lozano Palacio, Fernando, Carrión Puig, Albert, Aula Olivar, Ana, De Torres Ramírez, Inés M, Trilla Herrera, Enrique

“…Background & Objectives: We aimed to evaluate the risk of progression in high-grade T1 (HGT1) tumors using tumor budding (TB) and other standard clinical and…”
Get more information

Prevalence of Osteoporosis During Long-Term Androgen Deprivation Therapy in Patients with Prostate Cancer by Morote, Juan, Morin, Jacques Planas, Orsola, Anna, Abascal, Jose M, Salvador, Carles, Trilla, Enrique, Raventos, Carles X, Cecchini, Lluis, Encabo, Gloria, Reventos, Jaume

“…Objectives To know the prevalence of osteoporosis in patients with prostate cancer according to the duration of androgen deprivation therapy (ADT). Methods…”
Get full text

Effect of androgen deprivation therapy in the thyroid function test of patients with prostate cancer by Morote, Juan, Esquena, Salvador, Orsola, Anna, Salvador, Carlos, Trilla, Enrique, Cecchini, Luis, Raventós, Carles X, Planas, Jacques, Catalán, Roberto, Reventós, Jaume

“…We have assessed the effect of androgen deprivation therapy (ADT) in the thyroid function test in prostate cancer patients. Serum levels of tri-iodothyronine…”
Get full text

Bone mineral density changes in patients with prostate cancer during the first 2 years of androgen suppression by Morote, Juan, Orsola, Anna, Abascal, Jose M, Planas, Jacques, Trilla, Enrique, Raventos, Carles X, Cecchini, Lluis, Encabo, Gloria, Reventos, Jaume

“…We characterized bone mineral density changes in patients with prostate cancer on androgen deprivation therapy during the first 2 years of uninterrupted…”
Get more information

Measurement of free PSA in the diagnosis and staging of prostate cancer by Morote, Juan, Raventós, Carles X., Lorente, José A., Lopez‐Pacios, Miguel A., Encabo, Gloria, de Torres, Inés, Andreu, Jordi

“…The purpose of this study was to analyze the role of total prostate‐specific‐antigen (PSA) and free‐PSA levels in the diagnosis and clinical staging of…”
Get full text

PD18-08 ACTIVE SURVEILLLANCE IN LOW RISK BLADDER CANCER. IS IT A SAFE OPTION? by Lozano, Fernando, Raventos, Carles X, Carrion, Albert, Ropero, Jordi, Allue, Marta, Castro, Luis A, Cocera, Raul, Morote, Juan

Get full text

Effect of high-grade prostatic intraepithelial neoplasia on total and percent free serum prostatic-specific antigen by Morote, J, Raventós, C X, Encabo, G, López, M, de Torres, I M

“…To analyze the influence of high-grade prostatic intraepithelial neoplasia (HGPIN) on total serum prostatic-specific antigen (PSA) and percent free PSA. Total…”
Get more information